Sourcing & Management of Health Products

The Global Fund / Karin Schermbrucker

Antimalarial Medicines

115 million
life-saving antimalarial treatments procured in 2018 through pooled procurement and private sector co-payment mechanisms

A commitment to responsible and sustainable procurement guides our strategy of increasing access to all World Health Organization-recommended antimalarial medicines and formulations through Global Fund-supported programs.

We work with technical and implementing partners to understand the full demand picture for medicines used in malaria health programs. All World Health Organization-recommended antimalarial medicines are available through our Pooled Procurement Mechanism on our online purchasing platform,, and we frequently update our reference prices and Procurement and Delivery Planning Guide with up-to-date indicative lead times.

  • Category and Product-Level Procurement and Delivery Planning Guide: Indicative Lead Times
    download in English | Français
  • Pooled Procurement Mechanism Reference Pricing: Antimalarial Medicines
    download in English

Artemisinin manufacturing

The market for artemisinin, the main active pharmaceutical ingredient in many antimalarial medicines, has historically experienced speculative price instability, limited demand visibility and low oversight. A consultative process with artemisinin manufacturers in 2016 explored options for reliable, sustainable and responsible supply. In 2017, we required finished dosage form manufacturers to establish long-term agreements with artemisinin manufacturers, including semisynthetic sources, to strengthen supply security, stabilize pricing and incentivize best practices related to the health, safety and environmental risks of artemisinin extraction.

In addition to working upstream with artemisinin manufacturers, we have established current long-term agreements with antimalarial medicines manufacturers. We have incentivized manufacturers to offer both high- and low-volume products, to source a proportion of artemisinin from semisynthetic sources and to move production closer to the demand footprint. Health programs in countries most affected by malaria now benefit from shorter lead times and reduced transportation costs for quality-assured, life-saving antimalarial medicines.

The Global Fund is committed to increasing access to quality-assured antimalarial medicines. Other public sector buyers should reach out to Anne-Sophie Briand at to learn how to access our negotiated terms and pricing.

Documents related to our strategy, past tenders and reference prices are available for download here.

Private Sector Co-Payment Mechanism

The Private Sector Co-Payment Mechanism is a financing model used by the Global Fund to expand access to quality-assured ACTs, the most effective antimalarial medicines available today, through private sector distribution channels. The mechanism is well suited for countries where the private retail sector is a major provider of antimalarial medicines and currently operates in six countries.

The Private Sector Co-Payment Mechanism, along with its predecessor the Affordable Medicines Facility - malaria (AMFm), has demonstrated significant results in terms of lowering retail prices to patients and increasing access to quality-assured ACTs. The model leverages Global Fund-negotiated ACT prices and further reduces the price to pharmaceutical importers in participating countries through a co-payment made by the Global Fund directly to manufacturers on their behalf. Country-led supporting interventions, such as large-scale mass communications around treatment seeking for malaria, are instrumental in rapid and large changes in price, availability and market share of quality-assured ACTs.

Several key actors – including implementing partners, national governments, ACT manufacturers, Local Fund Agents and participating pharmaceutical importers – work together to enable the co-payment mechanism to achieve its objectives.

Reference documents are available for download.